WO2010008831A3 - Compounds and methods for modulating g protein-coupled receptors - Google Patents

Compounds and methods for modulating g protein-coupled receptors Download PDF

Info

Publication number
WO2010008831A3
WO2010008831A3 PCT/US2009/048265 US2009048265W WO2010008831A3 WO 2010008831 A3 WO2010008831 A3 WO 2010008831A3 US 2009048265 W US2009048265 W US 2009048265W WO 2010008831 A3 WO2010008831 A3 WO 2010008831A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
protein
methods
modulating
coupled receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/048265
Other languages
French (fr)
Other versions
WO2010008831A2 (en
Inventor
Xiaohui He
Xuefeng Zhu
Kunyong Yang
Robert Epple
Hong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2009271328A priority Critical patent/AU2009271328B2/en
Priority to KR1020117001655A priority patent/KR101273765B1/en
Priority to MX2010014569A priority patent/MX2010014569A/en
Priority to CN2009801243525A priority patent/CN102076670B/en
Priority to BRPI0914629A priority patent/BRPI0914629A2/en
Priority to US12/999,887 priority patent/US8362050B2/en
Priority to JP2011516523A priority patent/JP5400878B2/en
Priority to CA2729212A priority patent/CA2729212C/en
Application filed by IRM LLC filed Critical IRM LLC
Priority to EP09789895A priority patent/EP2300442A2/en
Priority to EA201100062A priority patent/EA019001B1/en
Publication of WO2010008831A2 publication Critical patent/WO2010008831A2/en
Publication of WO2010008831A3 publication Critical patent/WO2010008831A3/en
Anticipated expiration legal-status Critical
Priority to US13/693,876 priority patent/US20130096165A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.
PCT/US2009/048265 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors Ceased WO2010008831A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2011516523A JP5400878B2 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating G protein coupled receptors
MX2010014569A MX2010014569A (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors.
CN2009801243525A CN102076670B (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors
BRPI0914629A BRPI0914629A2 (en) 2008-06-24 2009-06-23 compounds and methods for modulating g protein-coupled receptors
US12/999,887 US8362050B2 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating G protein-coupled receptors
CA2729212A CA2729212C (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors
EP09789895A EP2300442A2 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors
AU2009271328A AU2009271328B2 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating G protein-coupled receptors
KR1020117001655A KR101273765B1 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors
EA201100062A EA019001B1 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors
US13/693,876 US20130096165A1 (en) 2008-06-24 2012-12-04 Compounds and methods for modulating g protein-coupled receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7509408P 2008-06-24 2008-06-24
US61/075,094 2008-06-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/693,876 Division US20130096165A1 (en) 2008-06-24 2012-12-04 Compounds and methods for modulating g protein-coupled receptors

Publications (2)

Publication Number Publication Date
WO2010008831A2 WO2010008831A2 (en) 2010-01-21
WO2010008831A3 true WO2010008831A3 (en) 2010-09-30

Family

ID=41445587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048265 Ceased WO2010008831A2 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors

Country Status (11)

Country Link
US (2) US8362050B2 (en)
EP (1) EP2300442A2 (en)
JP (1) JP5400878B2 (en)
KR (1) KR101273765B1 (en)
CN (1) CN102076670B (en)
AU (1) AU2009271328B2 (en)
BR (1) BRPI0914629A2 (en)
CA (1) CA2729212C (en)
EA (1) EA019001B1 (en)
MX (1) MX2010014569A (en)
WO (1) WO2010008831A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047569T2 (en) 2003-04-11 2020-04-28 Ptc Therapeutics Inc 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK2968471T3 (en) * 2013-03-01 2017-10-23 Fundació Hospital Univ Vall D' Hebron - Inst De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, especially in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
AU2015220427B2 (en) 2014-02-19 2017-09-21 Piramal Enterprises Limited Compounds for use as GPR120 agonists
KR102497273B1 (en) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
JP2017521441A (en) 2014-07-15 2017-08-03 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ Aryl-triazolylpyridines as pest control agents
AU2015293541B2 (en) 2014-07-25 2019-11-21 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
EP3191463B1 (en) 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
BR112017013465A2 (en) * 2014-12-24 2018-03-06 Lg Chem, Ltd biaryl derivative, and pharmaceutical composition.
US10941133B2 (en) 2015-02-05 2021-03-09 Piramal Enterprises Limited Compounds containing carbon-carbon linker as GPR120 agonists
JP2018531975A (en) 2015-10-30 2018-11-01 ピーティーシー セラピューティクス，インコーポレーテッド How to treat epilepsy
CN109475756A (en) * 2016-02-17 2019-03-15 儿童医疗中心有限公司 FFA1 (GPR40) as a therapeutic target for neuroangiogenic diseases or disorders
WO2017165139A1 (en) * 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
US20180126000A1 (en) 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
CN106279057B (en) * 2016-08-15 2022-04-15 广州明药科技有限公司 Synthetic method of Ataluren
US12411144B2 (en) * 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
BR112020010694A2 (en) 2017-12-01 2020-11-10 Abbvie Inc. glucocorticoid receptor agonist and immunoconjugates of the same
US20210163425A1 (en) 2017-12-20 2021-06-03 Gyeonggido Business & Science Accelerator Triazole derivative and use thereof
CA3148831A1 (en) * 2019-07-26 2021-02-04 Pedram HAMRAH A dermal patch for transdermal administration of ghrelin pathway blocker
CN113754541B (en) * 2020-06-02 2025-01-03 深圳湾实验室 Small molecule inhibitor targeting Epstein-Barr virus nuclear antigen protein, preparation method and application thereof
JPWO2022168962A1 (en) * 2021-02-04 2022-08-11
EP4511361A1 (en) * 2022-04-21 2025-02-26 Virginia Commonwealth University Nlrp3 inflammasome inhibitors and compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006122011A2 (en) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU497898B2 (en) * 1975-01-10 1979-01-18 Commonwealth Scientific And Industrial Research Organisation Plant growth regulating method and composition for use therein
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
DE2910861A1 (en) * 1979-03-20 1980-10-02 Basf Ag REACTIVE DYES
WO1996011210A1 (en) * 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19620041A1 (en) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhesion receptor antagonists
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2001316378A (en) * 2000-04-28 2001-11-13 Takeda Chem Ind Ltd Benzamide derivative and its use
EP1405636A4 (en) * 2001-06-26 2009-04-15 Takeda Pharmaceutical REGULATOR OF RECTINTOR FUNCTION RELATING TO RETINOIDS
JP2005162612A (en) * 2002-01-09 2005-06-23 Ajinomoto Co Inc Acylsulfonamide derivative
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
HUE047569T2 (en) * 2003-04-11 2020-04-28 Ptc Therapeutics Inc 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
WO2005051373A1 (en) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent
JPWO2005108370A1 (en) * 2004-04-16 2008-03-21 味の素株式会社 Benzene compounds
JP5222561B2 (en) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 Nitrogen-containing aromatic heterocyclic compound and pharmaceutical composition containing the same
JP2008001690A (en) 2006-05-26 2008-01-10 Pharma Frontier Kk Agonist of g protein coupled receptor, and medicine
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
JP2008195625A (en) 2007-02-08 2008-08-28 Pharma Frontier Kk G protein-coupled receptor inhibitor and medicine
AU2008218950A1 (en) 2007-02-22 2008-08-28 Irm Llc Thiazole derivatives as modulators of G protein-coupled receptors
JP5175866B2 (en) 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and methods for modulating G protein coupled receptors
EP2151236A4 (en) 2007-04-26 2013-01-16 Japan Science & Tech Agency G PROTEIN COUPLED RECEPTOR AGONIST
WO2008139879A1 (en) 2007-04-26 2008-11-20 Pharmafrontier, Co., Ltd. G protein-coupled receptor inhibitor and pharmaceutical product
CA2725316A1 (en) 2008-06-02 2009-12-10 Banyu Pharmaceutical Co., Ltd. Novel isoxazole derivative
AR074760A1 (en) 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006122011A2 (en) * 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use

Also Published As

Publication number Publication date
AU2009271328A1 (en) 2010-01-21
CA2729212A1 (en) 2010-01-21
CA2729212C (en) 2014-04-01
BRPI0914629A2 (en) 2019-09-24
CN102076670A (en) 2011-05-25
US8362050B2 (en) 2013-01-29
EA019001B1 (en) 2013-12-30
CN102076670B (en) 2013-05-22
JP5400878B2 (en) 2014-01-29
MX2010014569A (en) 2011-03-29
US20110172278A1 (en) 2011-07-14
WO2010008831A2 (en) 2010-01-21
EP2300442A2 (en) 2011-03-30
AU2009271328B2 (en) 2012-09-06
EA201100062A1 (en) 2011-08-30
KR20110022693A (en) 2011-03-07
US20130096165A1 (en) 2013-04-18
KR101273765B1 (en) 2013-06-12
JP2011525534A (en) 2011-09-22

Similar Documents

Publication Publication Date Title
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2012037411A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
WO2007076070A3 (en) Modulators of muscarinic receptors
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
WO2010003120A3 (en) Antagonists of prostaglandin d2 receptors
WO2010077882A3 (en) Antagonists of lysophosphatidic acid receptors
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
WO2008021375A3 (en) Modulators of muscarinic receptors
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010141761A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2007100664A3 (en) Modulators of muscarinic receptors
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2010008864A3 (en) Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
WO2010085820A3 (en) Tricyclic compounds as antagonists of prostaglandin d2 receptors
WO2006058294A3 (en) Modulators of muscarinic receptors
WO2006023852A3 (en) Modulators of muscarinic receptors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124352.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09789895

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/014569

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2729212

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011516523

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009271328

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009789895

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 397/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201100062

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20117001655

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009271328

Country of ref document: AU

Date of ref document: 20090623

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12999887

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0914629

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101223